CK 2130

Drug Profile

CK 2130

Latest Information Update: 30 Aug 2004

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Cardiotonics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Ischaemic heart disorders

Most Recent Events

  • 15 Jun 2004 Discontinued - Preclinical for Ischaemic heart disorders (unspecified route)
  • 31 Dec 1994 Discontinued - Uspecified phase in Heart failure in USA (Unknown route)
  • 31 Dec 1994 Preclinical development for Ischaemic heart disorders (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top